GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NIOX Group PLC (OTCPK:CSSPF) » Definitions » Debt-to-EBITDA

NIOX Group (NIOX Group) Debt-to-EBITDA : 0.16 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is NIOX Group Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

NIOX Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.76 Mil. NIOX Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.63 Mil. NIOX Group's annualized EBITDA for the quarter that ended in Dec. 2023 was $8.61 Mil. NIOX Group's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.16.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for NIOX Group's Debt-to-EBITDA or its related term are showing as below:

CSSPF' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -9.11   Med: 0.07   Max: 0.45
Current: 0.13

During the past 13 years, the highest Debt-to-EBITDA Ratio of NIOX Group was 0.45. The lowest was -9.11. And the median was 0.07.

CSSPF's Debt-to-EBITDA is ranked better than
84.19% of 430 companies
in the Medical Devices & Instruments industry
Industry Median: 1.235 vs CSSPF: 0.13

NIOX Group Debt-to-EBITDA Historical Data

The historical data trend for NIOX Group's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NIOX Group Debt-to-EBITDA Chart

NIOX Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.11 -0.17 0.45 0.07 0.13

NIOX Group Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.30 0.07 0.14 0.14 0.16

Competitive Comparison of NIOX Group's Debt-to-EBITDA

For the Medical Devices subindustry, NIOX Group's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NIOX Group's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NIOX Group's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where NIOX Group's Debt-to-EBITDA falls into.



NIOX Group Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

NIOX Group's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.759 + 0.633) / 10.886
=0.13

NIOX Group's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.759 + 0.633) / 8.608
=0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.


NIOX Group  (OTCPK:CSSPF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


NIOX Group Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of NIOX Group's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


NIOX Group (NIOX Group) Business Description

Traded in Other Exchanges
Address
Edmund Halley Road, Hayakawa Building, The Oxford Science Park, Oxford, GBR, OX4 4GB
NIOX Group PLC is a medical device company that develops a range of therapies for asthma, chronic obstructive pulmonary disease, and allergy. The company has a single operating segment: NIOX. The NIOX segment relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO). Geographically, it derives a majority of its revenue from the Asia Pacific and also has a presence in the European Union, the United States, the United Kingdom, and the Rest of the world.

NIOX Group (NIOX Group) Headlines